Edwards E, Whitaker-Azmitia P M, Harkins K
Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook 11794-8191.
Neuropsychopharmacology. 1990 Apr;3(2):129-36.
The effect of the putative 5-HT1A agonists 8-OH-DPAT and ipsapirone and 5-HT1B agonists TFMPP and m-CPP on respiratory activity in rats has been examined. In chloral hydrate-anesthetized rats, respiratory counts were decreased in a dose-dependent manner by both TFMPP and m-CPP, with an ED50 of 0.30 mg/kg (1.1 mumol/kg) and 3.0 mg/kg (11.0 mumol/kg) respectively. In contrast, both 5-HT1A agonists tested, 8-OH-DPAT and ipsapirone, produced an increase in respiratory rate at all doses tested. Moreover, the TFMPP-induced decrease in respiratory rate was antagonized by 8-OH-DPAT. The 5-HT2 antagonist ketanserin had no effect on the TFMPP-induced decrease in respiratory activity. However, methylsergide (5-HT1/5-HT2 antagonist) and (-)-cyanopindolol (5-HT1B antagonist) antagonized the TFMPP-induced respiratory rate decrease. The results of these experiments, coupled with the predominant presence of 5-HT1B receptors in the lower brainstem, pons, and medulla, as established by autoradiography studies, suggest a possible involvement of the 5-HT1B receptor subtype in the control of respiratory mechanisms, especially those involved in respiratory rhythmicity.
研究了假定的5-羟色胺1A(5-HT1A)激动剂8-羟基二丙基氨基四氢吡啶(8-OH-DPAT)和 ipsapirone以及5-羟色胺1B(5-HT1B)激动剂三氟甲基苯基哌嗪(TFMPP)和间氯苯哌嗪(m-CPP)对大鼠呼吸活动的影响。在水合氯醛麻醉的大鼠中,TFMPP和m-CPP均以剂量依赖性方式降低呼吸次数,其半数有效剂量(ED50)分别为0.30毫克/千克(1.1微摩尔/千克)和3.0毫克/千克(11.0微摩尔/千克)。相比之下,所测试的两种5-HT1A激动剂,即8-OH-DPAT和ipsapirone,在所有测试剂量下均使呼吸频率增加。此外,8-OH-DPAT可拮抗TFMPP引起的呼吸频率降低。5-羟色胺2(5-HT2)拮抗剂酮色林对TFMPP引起的呼吸活动降低没有影响。然而,甲基麦角新碱(5-HT1/5-HT2拮抗剂)和(-)-氰基吲哚洛尔(5-HT1B拮抗剂)可拮抗TFMPP引起的呼吸频率降低。这些实验结果,再结合放射自显影研究确定的5-HT1B受体在下脑干、脑桥和延髓中占主导地位,表明5-HT1B受体亚型可能参与呼吸机制的控制,尤其是那些参与呼吸节律的机制。